Medical Disclaimers

Please review the important safety information below for intended use, limitations of use, risks, warnings, precautions, possible side effects, use in specific populations, and medication interactions for the treatments facilitated by Trueform. This information is not a substitute for medical advice, diagnosis, or treatment. Patients should consult their licensed healthcare practitioner regarding whether any treatment is appropriate for their individual medical history, goals, and current medications.

In the event of a medical emergency, call 10177 (national ambulance) or 112 (emergency from a mobile phone), or go to the nearest hospital emergency room immediately. Patients should promptly report side effects, unexpected reactions, or other safety concerns to their care team. Suspected adverse reactions may also be reported to the South African Health Products Regulatory Authority (SAHPRA) through its adverse drug reaction reporting system at https://primaryreporting.sahpra.org.za.

Trueform is a technology and administrative services platform that facilitates access to telehealth consultations with licensed healthcare practitioners. Trueform does not itself practise medicine, provide medical advice, manufacture medications, compound medications, or dispense medications. Any prescription is issued solely at the independent clinical judgement of a licensed healthcare practitioner, if the practitioner determines that treatment is medically appropriate for the patient. If a prescription is written, it will be processed by a designated courier pharmacy unless otherwise expressly requested by the patient.

Prescription treatment is not guaranteed. Not every patient is a candidate for every treatment. Eligibility, prescribing decisions, dosage, treatment duration, refill decisions, and ongoing monitoring are determined by the treating practitioner based on clinical appropriateness and applicable law. Product availability may vary by patient profile, pharmacy supply, and other factors.

Advertisements and website content made available by Trueform are for informational and marketing purposes only. Images may depict sample packaging, stock photography, or illustrative representations. Actual medication packaging, labelling, dosage form, concentration, device configuration, and instructions may differ from what is shown.

All prescription medications carry risks, including the risk of serious side effects, allergic reactions, multi–drug interactions, contraindications, and adverse outcomes in certain patient populations. Patients should carefully review all prescribing information, patient information leaflets, pharmacy labelling, and instructions for use that accompany their prescribed medication. Patients should tell their practitioner about all medical conditions, allergies, prior adverse drug reactions, pregnancy or breastfeeding status, and all prescription drugs, over-the-counter medications, supplements, and herbal products they use.

Patients should not start, stop, substitute, or combine prescription treatments without guidance from a licensed healthcare practitioner. Prescription medications should be used only as prescribed and should never be shared with another person. Patients should review all pharmacy-specific instructions and ask their practitioner or pharmacist about formulation-specific storage, administration, timing, and side effect expectations.

Trueform facilitates access to compounded medications prescribed by a licensed healthcare practitioner and manufactured by a licensed compounding pharmacy. Compounded medications are custom-prepared formulations tailored to individual patient needs. They are not registered with SAHPRA and have not undergone the same regulatory review process as registered pharmaceutical products in terms of safety, efficacy, and quality.

Compounded medications are prescribed at the independent clinical judgement of the treating healthcare practitioner and dispensed in accordance with applicable South African law, including the Medicines and Related Substances Act (Act 101 of 1965) and relevant pharmacy practice requirements.

Patients should not assume that compounded medications are the same as registered pharmaceutical products containing the same active ingredient. The active ingredient source, inactive ingredients (excipients), concentration, dosage form, route of administration, packaging, storage requirements, and pharmacy labelling may differ.

Certain medications referenced on this site contain semaglutide or tirzepatide and carry important warnings regarding the risk of thyroid C-cell tumours. These medications should not be used in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumours. It is unknown whether these medications cause thyroid C-cell tumours, including MTC, in humans.

Patients should promptly seek medical evaluation if they develop a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. Patients should discuss all risks, contraindications, warnings, and precautions with their licensed healthcare practitioner.

Semaglutide- and tirzepatide-containing therapies may also be associated with gastrointestinal side effects and serious risks including, where applicable, nausea, vomiting, diarrhoea, constipation, abdominal pain, delayed gastric emptying, dehydration, kidney injury, gallbladder problems, pancreatitis, hypoglycaemia when used with insulin or insulin secretagogues, worsening diabetic retinopathy in certain patients, heart rate increase in some cases, pulmonary aspiration risk during general anaesthesia or deep sedation in some settings, and serious hypersensitivity reactions. Patients should confirm their existing medications with their prescribing practitioner as there may be possible medication interaction concerns, including with oral contraceptives in certain cases.

These treatments may not be appropriate for all patients. Patients should discuss all risks, warnings, and precautions with their prescribing practitioner before starting therapy and during ongoing treatment.Patients should promptly contact their practitioner if they experience severe, persistent, or concerning symptoms.

Unless specifically directed by a licensed healthcare practitioner, semaglutide- or tirzepatide-containing therapies generally should not be combined with other medications in the same class or with other products intended for weight loss without careful clinical review. Patients should also discuss pregnancy plans, contraception, breastfeeding status, any planned surgery or procedure, and the use of oral medications that may be affected by delayed gastric emptying.

"GLP-1 microdose" refers to a lower-dose treatment approach involving semaglutide or tirzepatide that may be considered by a licensed healthcare practitioner for certain patients. These are not a separate registered medication products. Even at lower doses, semaglutide-containing therapies may carry meaningful risks and are not appropriate for all patients. Potential risks may include gastrointestinal side effects, dehydration, kidney injury, gallbladder problems, pancreatitis, delayed gastric emptying, low blood sugar when used with certain diabetes medications, and serious allergic reactions. Patients should not assume that a lower dose eliminates the need for clinical oversight, screening, titration, monitoring, or adherence to practitioner instructions.

Patients who are pregnant, planning to become pregnant, or breastfeeding should discuss this with their practitioner before starting any treatment referenced on this site. Certain semaglutide- and tirzepatide-containing products may not be appropriate during pregnancy or breastfeeding, and treatment may need to be stopped in advance of a planned pregnancy. Patients using oral contraceptives or other time-sensitive oral medications should discuss potential absorption or efficacy considerations with their practitioner.

Before starting treatment, patients should disclose all relevant medical history and all medications, vitamins, supplements, and herbal products they use. This includes diabetes medications, insulin, sulfonylureas, thyroid medications, anticoagulants, oral contraceptives, and any other prescription or over-the-counter products. Certain GLP-1-related therapies may affect gastric emptying and medication absorption, and combination use with some diabetes therapies may increase the risk of hypoglycaemia.

Individual response to treatment varies. Not all patients will experience the same outcomes, side effects, tolerability, or speed of response. Any examples, testimonials, or descriptions of results are not guarantees of future outcomes. Clinical appropriateness, adherence, follow-up, diet, exercise, coexisting conditions, medication availability, and many other variables may affect results.

For questions about Trueform's services, patients should email hello@trueform.co.za or WhatsApp +27 79 852 8361

For questions about a prescribed medication, side effects, administration, storage, or whether a treatment remains appropriate, patients should address their query to their care team via email at care@trueform.co.za or request a callback via WhatsApp on +27 79 852 8361 .